既往完成新冠mRNA疫苗基础免疫的健康日本成人接种单剂NVX-CoV2373(TAK-019)加强针的免疫原性与安全性:一项3期开放标签试验的主要分析报告
这项在日本两个中心开展的单臂、开放标签3期研究,纳入150名已完成新冠mRNA疫苗基础免疫6至12个月的健康成人,接种单剂NVX-CoV2373加强针。针对原始株的血清中和抗体GMT比值(本研究第15天/TAK-019-1501研究第36天)为1.18(95%CI 0.95-1.47),达到非劣效标准;接种后7天内局部和全身征集性不良事件报告率分别为74.0%和48.0%,安全性可接受。
要点
- 单剂NVX-CoV2373异源加强后第15天中和抗体GMT较既往NVX-CoV2373基础免疫第36天比值1.18(95%CI 0.95-1.47),达到非劣效。
- 接种后7天内局部和全身征集性不良事件报告率分别为74.0%和48.0%,最常见分别为压痛(68.0%)和乏力(26.0%)。
- 接种至第28天,7名参与者(4.7%)报告非征集性不良事件,严重程度均≤2级。
核心结论
- 单剂异源NVX-CoV2373加强针可诱导快速且稳健的抗SARS-CoV-2免疫应答,应对健康日本成人免疫衰减,且安全性可接受。
研究设计与样本
- 单臂、开放标签、3期研究,在日本两个中心开展,纳入150名≥20岁、已完成新冠mRNA疫苗基础免疫6至12个月的健康成人,按年龄分层(20-64岁n=135,≥65岁n=15),均接种单剂NVX-CoV2373加强针。
主要发现
- 本研究第15天针对SARS-CoV-2原始株的血清中和抗体GMT与TAK-019-1501研究第36天的GMT比值为1.18(95%CI 0.95-1.47),达到非劣效标准(95%CI下限≥0.67)。
- 接种后7天内局部征集性不良事件报告率为74.0%,全身征集性不良事件报告率为48.0%。
- 最常见的局部征集性不良事件为压痛(102名参与者,68.0%),最常见的全身征集性不良事件为乏力(39名参与者,26.0%)。
- 接种至第28天,7名参与者(4.7%)报告非征集性不良事件,所有事件严重程度均≤2级。
关键数值与推荐
- 主要免疫原性终点为非劣效:本研究第15天与TAK-019-1501研究第36天血清中和抗体GMT比值的95%CI下限≥0.67。
- 实际GMT比值为1.18(95%CI 0.95-1.47),满足非劣效标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated the immunogenicity and safety of a booster dose of NVX-CoV2373 in Japanese adults who had completed a primary series of COVID-19 mRNA vaccine 6-12 months previously. METHODS: This single-arm, open-label, phase 3 study, conducted at two Japanese centres, enrolled healthy adults ≥ 20 years old. Participants received a booster dose of NVX-CoV2373. The primary immunogenicity endpoint was non-inferiority (lower limit of the 95 % confidence interval [CI] ≥ 0.67) of the geometric mean titre (GMT) ratio of titres of serum neutralizing antibodies (nAbs) against the SARS-CoV-2 ancestral strain 14 days after booster vaccination (day 15) in this study, compared with those 14 days after the second primary NVX-CoV2373 vaccination (day 36) in the TAK-019-1501 study (NCT04712110). Primary safety endpoints included local and systemic solicited adverse events (AEs) up to day 7 and unsolicited AEs up to day 28. RESULTS: Between 15 April 2022 and 10 May 2022, 155 participants were screened and 150, stratified by age (20-64 years old [n = 135] or ≥ 65 years old [n = 15]), received an NVX-CoV2373 booster dose. The GMT ratio between titres of serum nAbs against the SARS-CoV-2 ancestral strain on day 15 in this study and those on day 36 in the TAK-019-1501 study was 1.18 (95 % CI, 0.95-1.47), meeting the non-inferiority criterion. Following vaccination, the proportion of participants who reported local and systemic solicited AEs up to day 7 was 74.0 % and 48.0 %, respectively. The most common local and systemic solicited AEs were tenderness (102 participants [68.0 %]) and malaise (39 participants [26.0 %]), respectively. Seven participants (4.7 %) reported unsolicited AEs between vaccination and day 28; all were severity grade ≤ 2. DISCUSSION: A single heterologous NVX-CoV2373 booster induced rapid and robust anti-SARS-CoV-2 immune responses, addressing waning immunity in healthy Japanese adults, and had an acceptable safety profile. CLINICALTRIALS: gov identifier: NCT05299359.
引用
- Kuriyama K, Murakami K, Masuda T, et al. Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial. Vaccine. 2023. PMID: 37198021. doi:10.1016/j.vaccine.2023.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。